Rock Springs Capital Management LP Kinnate Biopharma Inc. Transaction History

Rock Springs Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.38 - $3.31 $470,803 - $1.13 Million	-341,162 Reduced 45.67%	405,811 $568,000
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $1.27 Million - $2.03 Million	128,589 Added 20.79%	746,973 $8.93 Million
Q2 2022 Aug 15, 2022	BUY	$7.43 - $13.0 $2.04 Million - $3.57 Million	274,238 Added 79.69%	618,384 $7.8 Million
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $33,239 - $77,357	4,300 Added 1.27%	344,146 $3.88 Million
Q4 2021 Feb 14, 2022	BUY	$16.5 - $25.48 $113,190 - $174,792	6,860 Added 2.06%	339,846 $6.02 Million
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $24,934 - $34,818	1,400 Added 0.42%	332,986 $7.67 Million
Q2 2021 Aug 16, 2021	BUY	$22.19 - $31.55 $115,388 - $164,060	5,200 Added 1.59%	331,586 $7.72 Million
Q1 2021 May 17, 2021	BUY	$26.99 - $40.0 $45,883 - $68,000	1,700 Added 0.52%	326,386 $10.2 Million
Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $11.8 Million - $14.7 Million	324,686 New	324,686 $12.9 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.